# US 2012/0269849 A1 · Attenuated influenza viruses and vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269849 A1
- Document ID: US20120269849A1
- Status: Published application
- Kind: A1
- Application number: 13/501,045
- Filed: 2010-10-11
- Published: 2012-10-25
- Earliest claimed: 2009-10-09
- Inventors: Eckard Wimmer; Steve Skiena; Steffen Mueller; Bruce Futcher; Dimitris Papamichail; John Robert Coleman; Jeronimo Cello
- Web page: https://patentgrep.com/patent/US20120269849A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/12: Antivirals
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/543: {intranasal}
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16162: by genetic engineering
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present provides attenuated influenza viruses comprising a modified viral genome containing a plurality of nucleotide substitutions. The nucleotide substitutions result in the rearrangement of preexisting codons of one or more protein encoding sequences and changes in codon pair bias. Substitutions of non-synonymous and synonymous codons may also be included. The attenuated influenza viruses enable production of improved vaccines and are used to elicit protective immune responses.

## Claims

### Claim 1

An attenuated influenza virus genome which comprises a nucleic acid encoding nucleoprotein (NP), and a nucleic acid encoding a polymerase protein, wherein the codon pair bias of each of said nucleic acids is less than the codon pair bias of a parent nucleic acid from which it is derived.

### Claim 2 (depends on 1)

The attenuated influenza virus genome of claim 1, the polymerase protein is PB1.

### Claim 3 (depends on 1)

The attenuated influenza virus genome of claim 1, which further comprises a nucleic acid encoding a virion protein, wherein the codon pair bias of the virion protein nucleic acid is less that the codon pair bias of a parent nucleic acid from which it is derived.

### Claim 4 (depends on 3)

The attenuated influenza virus genome of claim 3, wherein the virion protein is hemagglutinin (HA).

### Claim 5 (depends on 1)

The attenuated influenza virus genome of claim 1, wherein the parent nucleic acid is from a natural isolate.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The attenuated influenza virus genome of any one of claims 1 to 5, wherein the codon pair bias is reduced by shuffling the codons of the parent nucleic acid.

### Claim 7 (depends on 3)

The attenuated influenza virus genome of claim 3, wherein the codon pair bias of one or more of the nucleic acids encoding nucleoprotein (NP), the virion protein, and the polymerase protein is at least 0.05 less than the codon pair bias of the parent nucleic acid.

### Claim 8 (depends on 3)

The attenuated influenza virus genome of claim 3, wherein the codon pair bias of one or more of the nucleic acids encoding nucleoprotein (NP), the virion protein, and the polymerase protein is less that −0.1.

### Claim 9 (depends on 3)

The attenuated influenza virus genome of claim 3, wherein the codon pair bias of one or more of the nucleic acids encoding nucleoprotein (NP), the virion protein, and the polymerase protein is less that −0.2.

### Claim 10 (depends on 3)

The attenuated influenza virus genome of claim 3, wherein the codon pair bias of one or more of the nucleic acids encoding nucleoprotein (NP), the virion protein, and the polymerase protein is less that −0.3.

### Claim 11 (depends on 3)

The attenuated influenza virus genome of claim 3, wherein the codon pair bias of one or more of the nucleic acids encoding nucleoprotein (NP), the virion protein, and the polymerase protein is less that −0.4.

### Claim 12 (depends on 1, 2, 3, 4, 5)

An attenuated influenza virus which comprises the attenuated influenza virus genome of any one of claims 1 to 5.

### Claim 13 (depends on 12)

The attenuated influenza virus of claim 12, wherein the attenuated influenza virus infects a human.

### Claim 14 (depends on 12)

The attenuated influenza virus of claim 12, wherein the attenuated influenza virus infects a bird.

### Claim 15 (depends on 12)

The attenuated influenza virus of claim 12, wherein the attenuated influenza virus infects a pig.

### Claim 16

A vaccine composition for inducing a protective immune response in a subject, wherein the vaccine composition comprises a nucleic acid encoding nucleoprotein (NP) and a nucleic acid encoding a polymerase protein, wherein the codon pair bias of each of said nucleic acids is less than the codon pair bias of a parent nucleic acid from which it is derived.

### Claim 17 (depends on 16)

The vaccine composition of claim 16, which further comprises a nucleic acid encoding a virion protein, wherein the codon pair bias of the virion protein nucleic acid is less that the codon pair bias of a parent nucleic acid from which it is derived.

### Claim 18 (depends on 16)

A method of eliciting a protective immune response in a subject comprising administering to the subject a prophylactically or therapeutically effective dose of the vaccine composition of claim 16.

### Claim 19 (depends on 18)

The method of claim 18, further comprising administering to the subject at least one adjuvant.

### Claim 20

A method of making an attenuated influenza virus genome comprising:
a) obtaining the nucleotide sequence encoding the nucleoprotein (NP) of an influenza virus and the nucleotide sequence encoding a polymerase protein of an influenza virus;
b) rearranging the codons of the nucleotide sequences to obtain mutated nucleotide sequences that
i) encode the same amino acid sequences as the unrearranged nucleotide sequences, and
ii) have a reduced codon pair bias compared to the unrearranged nucleotide sequence; and
c) substituting all or part of the mutated nucleotide sequences into the unrearranged nucleotides of the influenza virus genome.

### Claim 21 (depends on 20)

The method of claim 20, which further comprises obtaining the nucleotide sequence encoding a virion protein of an influenza virus;
b) rearranging the codons of the nucleotide sequence to obtain a mutated nucleotide sequence that
i) encodes the same amino acid sequence as the unrearranged nucleotide sequences, and
ii) has a reduced codon pair bias compared to the unrearranged nucleotide sequence; and
c) substituting all or part of the mutated nucleotide sequences into the unrearranged nucleotides of the influenza virus genome.

### Claim 22 (depends on 21)

The method of claim 21, wherein polymerase protein is PB1 and the virion protein is hemagglutinin (HA).
